Servier and Intercept Pharmaceuticals Announce Agreement in Type 2 Diabetes

09/08/2011

Neuilly sur Seine, France, August 09, 2011 - Les Laboratoires Servier (Servier) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an agreement for the discovery and development of novel TGR5 agonists for the treatment of type 2 diabetes and other metabolic indications. The collaboration will leverage Intercept’s drug discovery platform based on its proprietary bile acid analog chemistry and expertise targeting TGR5 and other bile receptors. 

TGR5 (GPR131) is a receptor that is regulated by bile acids, known to be key regulators of lipid, and glucose metabolism, and energy homeostasis. 

The collaboration will leverage Intercept’s drug discovery platform based on its proprietary bile acid analog chemistry and expertise targeting TGR5 and other bile receptors. Under the terms of the agreement, Intercept and Servier will jointly support the discovery effort, while Servier alone will be responsible for all costs associated with the global worldwide ex-U.S. and Japan development, regulatory approval and commercialization of any compound selected as a lead candidate by the parties.